Polyphony: Superposition independent methods for ensemble-based drug discovery

BMC Bioinformatics

Volumn 15, Issue 1, 2014, Pages

  Pitt, William R ^a,b   Montalvão, Rinaldo W ^a,c   Blundell, Tom L ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UCB PHARMA   (Belgium)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DISCOVERY;

CYCLIN DEPENDENT KINASE 2; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE 14;

ALGORITHM; ARTICLE; BINDING SITE; BIOLOGY; CHEMISTRY; DRUG DESIGN; DRUG DEVELOPMENT; METABOLISM; METHODOLOGY; MOLECULAR DYNAMICS; PHOSPHORYLATION; PROTEIN CONFORMATION; X RAY CRYSTALLOGRAPHY;

ALGORITHMS; ALLOSTERIC SITE; COMPUTATIONAL BIOLOGY; CRYSTALLOGRAPHY, X-RAY; CYCLIN-DEPENDENT KINASE 2; DRUG DESIGN; DRUG DISCOVERY; LIGANDS; MITOGEN-ACTIVATED PROTEIN KINASE 14; MOLECULAR DYNAMICS SIMULATION; PHOSPHORYLATION; PROTEIN CONFORMATION;

EID: 84908060372     PISSN: None     EISSN: 14712105     Source Type: Journal    
DOI: 10.1186/1471-2105-15-324     Document Type: Article

References (101)

1. Teague S. Implications of protein flexibility for drug discovery. Nat Rev Drug Discov 2003, 2:527-541. 10.1038/nrd1129, 12838268.
2. Marco E, Gago F. Overcoming the inadequacies or limitations of experimental structures as drug targets by using computational modeling tools and molecular dynamics simulations. Chem Med Chem 2007, 2:1388-1401. 10.1002/cmdc.200700087, 17806089.
3. Schneider G. Virtual screening: an endless staircase?. Nat Rev Drug Discov 2010, 9:273-276. 10.1038/nrd3139, 20357802.
4. Frembgen-Kesner T, Elcock A. Computational sampling of a cryptic drug binding site in a protein receptor: explicit solvent molecular dynamics and inhibitor docking to p38 MAP kinase. J Mol Biol 2006, 359:202-214. 10.1016/j.jmb.2006.03.021, 16616932.
5. Pargellis C, Tong L, Churchill L, Cirillo P, Gilmore T, Graham A, Grob P, Hickey E, Moss N, Pav S, Regan J. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Mol Biol 2002, 9:268-272.
6. Hardy J, Wells J. Searching for new allosteric sites in enzymes. Curr Opin Struct Biol 2004, 14:706-715. 10.1016/j.sbi.2004.10.009, 15582395.
7. Arkin M, Wells J. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov 2004, 3:301-317. 10.1038/nrd1343, 15060526.
8. Best R, Lindorff-Larsen K, DePristo M, Vendruscolo M. Relation between native ensembles and experimental structures of proteins. Proc Natl Acad Sci U S A 2006, 103:10901-10906. 10.1073/pnas.0511156103, 1544146, 16829580.
9. Wasserman S, Koss J, Sojitra S, Morisco L, Burley S. Rapid-access, high-throughput synchrotron crystallography for drug discovery. Trends Pharmacol Sci 2012, 33:261-267. 10.1016/j.tips.2012.03.009, 22521107.
10. Furnham N, de Bakker PI, Gore S, Burke D, Blundell T. Comparative modelling by restraint-based conformational sampling. BMC Struct Biol 2008, 8:7. 10.1186/1472-6807-8-7, 2275734, 18237407.
11. De Groot B, van Aalten D, Scheek R, Amadei A, Vriend G, Berendsen H. Prediction of protein conformational freedom from distance constraints. Proteins 1997, 29:240-251. 10.1002/(SICI)1097-0134(199710)29:2<240::AID-PROT11>3.0.CO;2-O, 9329088.
12. Liwo A, Czaplewski C, Ołdziej S, Scheraga H. Computational techniques for efficient conformational sampling of proteins. Curr Opin Struct Biol 2008, 18:134-139. 10.1016/j.sbi.2007.12.001, 2465814, 18215513.
13. Carlson H, McCammon A. Accommodating protein flexibility in computational drug design. Mol Pharmacol 2000, 57:213-218.
14. Barril X, Fradera X. Incorporating protein flexibility into docking and structure-based drug design. Expert Opinion on Drug Discovery 2006, 1:335-349. 10.1517/17460441.1.4.335, 23495904.
15. Damm K, Carlson H. Exploring experimental sources of multiple protein conformations in structure-based drug design. J Am Chem Soc 2007, 129:8225-8235. 10.1021/ja0709728, 17555316.
16. Cozzini P, Kellogg G, Spyrakis F, Abraham D, Costantino G, Emerson A, Fanelli F, Gohlke H, Kuhn L, Morris G, Orozco M, Pertinhez T, Rizzi M, Sotriffer C. Target flexibility: an emerging consideration in drug discovery and design. J Med Chem 2008, 51:6237-6255. 10.1021/jm800562d, 2701403, 18785728.
17. Berman H, Westbrook J, Feng Z, Gilliland G, Bhat T, Weissig H, Shindyalov I, Bourne P. The protein data bank. Nucleic Acids Res 2000, 28:235-242. 10.1093/nar/28.1.235, 102472, 10592235.
18. Amadei A, Linssen A, Berendsen H. Essential dynamics of proteins. Proteins 1993, 17:412-425. 10.1002/prot.340170408, 8108382.
19. Van Aalten D, Conn D, de Groot B, Berendsen H, Findlay J, Amadei A. Protein dynamics derived from clusters of crystal structures. Biophys J 1997, 73:2891-2896. 10.1016/S0006-3495(97)78317-6, 1181194, 9414203.
20. Abseher R, Horstink L, Hilbers CW, Nilges M. Essential spaces defined by NMR structure ensembles and molecular dynamics simulation show significant overlap. Proteins: Structure, Function, and Bioinformatics 1998, 31:370-382.
21. Hess B, Kutzner C, van der Spoel D, Lindahl E. GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation. J Chem Theory Comput 2008, 4:435-447.
22. Grant B, Rodrigues A, ElSawy K, McCammon A, Caves L. Bio3d: an R package for the comparative analysis of protein structures. Bioinformatics (Oxford, England) 2006, 22:2695-2696.
23. Barrett P, Hall B, Noble M. Dynamite: a simple way to gain insight into protein motions. Acta Crystallographica Section D 2004, 60:2280-2287.
24. Seeber M, Cecchini M, Rao F, Settanni G, Caflisch A. Wordom: a program for efficient analysis of molecular dynamics simulations. Bioinformatics 2007, 23:2625-2627. 10.1093/bioinformatics/btm378, 17717034.
25. Bakan A, Meireles L, Bahar I. ProDy: protein dynamics inferred from theory and experiments. Bioinformatics 2011, 27:1575-1577. 10.1093/bioinformatics/btr168, 3102222, 21471012.
26. Echols N, Milburn D, Gerstein M. MolMovDB: analysis and visualization of conformational change and structural flexibility. Nucleic Acids Res 2003, 31:478-482. 10.1093/nar/gkg104, 165551, 12520056.
27. Hayward S, Lee R. Improvements in the analysis of domain motions in proteins from conformational change: DynDom version 1.50. J Mol Graph Model 2002, 21:181-183. 10.1016/S1093-3263(02)00140-7, 12463636.
28. Shatsky M, Nussinov R, Wolfson H. Flexible protein alignment and hinge detection. Proteins 2002, 48:242-256. 10.1002/prot.10100, 12112693.
29. Ye Y, Godzik A. FATCAT: a web server for flexible structure comparison and structure similarity searching. Nucleic Acids Res 2004, 32:W582-W585. 10.1093/nar/gkh430, 441568, 15215455.
30. Mu Y, Nguyen P, Stock G. Energy landscape of a small peptide revealed by dihedral angle principal component analysis. Proteins 2005, 58:45-52.
31. Domingues F, Rahnenführer J, Lengauer T. Conformational analysis of alternative protein structures. Bioinformatics 2007, 23:3131-3138. 10.1093/bioinformatics/btm499, 17933849.
32. Le Guilloux V, Schmidtke P, Tuffery P. Fpocket: An open source platform for ligand pocket detection. BMC Bioinformatics 2009, 10:1-11. 10.1186/1471-2105-10-1, 2631520, 19118496.
33. Ashford P, Moss D, Alex A, Yeap S, Povia A, Nobeli I, Williams M. Visualisation of variable binding pockets on protein surfaces by probabilistic analysis of related structure sets. BMC Bioinformatics 2012, 13:39. 10.1186/1471-2105-13-39, 3359218, 22417279.
34. Rø Gen P, Fain B. Automatic classification of protein structure by using Gauss integrals. Proc Natl Acad Sci 2003, 100:119-124. 10.1073/pnas.2636460100, 140900, 12506205.
35. Rackovsky S, Scheraga H. Differential geometry and polymer conformation. 1. Comparison of protein conformations1a, b. Macromolecules 1978, 11:1168-1174.
36. Chang P, Rinne A, Dewey G. Structure alignment based on coding of local geometric measures. BMC Bioinformatics 2006, 7:46. 10.1186/1471-2105-7-46, 1403810, 16441884.
37. Montalvão R, Smith R, Lovell S, Blundell T. CHORAL: a differential geometry approach to the prediction of the cores of protein structures. Bioinformatics 2005, 21:3719-3725. 10.1093/bioinformatics/bti595, 16046494.
38. Ranganathan S, Izotov D, Kraka E, Cremer D. Description and recognition of regular and distorted secondary structures in proteins using the automated protein structure analysis method. Proteins 2009, 76:418-438. 10.1002/prot.22357, 19205025.
39. Leung H, Montaño B, Blundell T, Vendruscolo M, Montalvão R. ARABESQUE: A tool for protein structural comparison using differential geometry and knot theory. World Res J Peptide Protein 2012, 1:33-40.
40. Göbel U, Sander C, Schneider R, Valencia A. Correlated mutations and residue contacts in proteins. Proteins 1994, 18:309-317. 10.1002/prot.340180402, 8208723.
41. Ccp4 The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 1994, 50:760-763. 10.1107/S0907444994003112, 15299374, Ccp4.
42. Schreyer A, Blundell T. CREDO: a protein-ligand interaction database for drug discovery. Chem Biol Drug Des 2009, 73:157-167. 10.1111/j.1747-0285.2008.00762.x, 19207418.
43. Bickerton G, Higueruelo A, Blundell T. Comprehensive, atomic-level characterization of structurally characterized protein-protein interactions: the PICCOLO database. BMC Bioinformatics 2011, 12:313. 10.1186/1471-2105-12-313, 3161047, 21801404.
44. Hunter J. Matplotlib: a 2D graphics environment. Comp Sci Eng 2007, 9:90-95.
45. The PyMOL molecular graphics system, version 1.2r1 Schrödinger, LLC. [http://www.pymol.org/].
46. Waterhouse A, Procter J, Martin D, Clamp M, Barton G. Jalview Version 2-a multiple sequence alignment editor and analysis workbench. Bioinformatics 2009, 25:1189-1191. 10.1093/bioinformatics/btp033, 2672624, 19151095.
47. Huerta-Cepas J, Dopazo J, Gabaldon T. ETE: a python environment for tree exploration. BMC Bioinformatics 2010, 11:24. 10.1186/1471-2105-11-24, 2820433, 20070885.
48. Barrett P, Noble M. Molecular motions of human cyclin-dependent kinase 2. J Biol Chem 2005, 280:13993-14005. 10.1074/jbc.M407371200, 15695825.
49. Tobi D, Bahar I. Structural changes involved in protein binding correlate with intrinsic motions of proteins in the unbound state. Proc Natl Acad Sci U S A 2005, 102:18908-18913. 10.1073/pnas.0507603102, 1323175, 16354836.
50. Barril X, Morley D. Unveiling the full potential of flexible receptor docking using multiple crystallographic structures. J Med Chem 2005, 48:4432-4443. 10.1021/jm048972v, 15974595.
51. Mazanetz MP, Withers IM, Laughton CA, Fischer PM. A study of CDK2 inhibitors using a novel 3D-QSAR method exploiting receptor flexibility. QSAR Comb Sci 2009, 28:878-884.
52. Sperandio O, Mouawad L, Pinto E, Villoutreix B, Perahia D, Miteva M. How to choose relevant multiple receptor conformations for virtual screening: a test case of Cdk2 and normal mode analysis. Eur Biophys J 2010, 39:1365-1372. 10.1007/s00249-010-0592-0, 20237920.
53. Bártová I, Koca J, Otyepka M. Functional flexibility of human cyclin-dependent kinase-2 and its evolutionary conservation. Protein Sci 2008, 17:22-33. 2144583, 18042686.
54. Johnson L. Protein kinase inhibitors: contributions from structure to clinical compounds. Q Rev Biophys 2009, 42:1-40. 10.1017/S0033583508004745, 19296866.
55. Duca J. Recent advances on structure-informed drug discovery of cyclin-dependent kinase-2 inhibitors. Future Med Chem 2009, 1:1453-1466. 10.4155/fmc.09.102, 21426059.
56. Takaki T, Echalier A, Brown N, Hunt T, Endicott J, Noble M. The structure of CDK4/cyclin D3 has implications for models of CDK activation. Proc Natl Acad Sci 2009, 106:4171-4176. 10.1073/pnas.0809674106, 2657433, 19237555.
57. Pavletich N. Mechanisms of cyclin-dependent kinase regulation: structures of cdks, their cyclin activators, and cip and INK4 inhibitors. J Mol Biol 1999, 287:821-828. 10.1006/jmbi.1999.2640, 10222191.
58. Jeffrey P, Russo A, Polyak K, Gibbs E, Hurwitz J, Massague J, Pavletich N. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 1995, 376:313-320. 10.1038/376313a0, 7630397.
59. Russo A, Jeffrey P, Pavletich N. Structural basis of cyclin-dependent kinase activation by phosphorylation. Nat Struct Mol Biol 1996, 3:696-700.
60. Bao ZQ, Jacobsen D, Young M. Briefly bound to activate: transient binding of a second catalytic magnesium activates the structure and dynamics of CDK2 kinase for catalysis. Structure (London, England: 1993) 2011, 19:675-690.
61. Redundancy in the Protein Data Bank. [http://www.rcsb.org/pdb/statistics/clusterStatistics.do].
62. Schulze-Gahmen U, De Bondt H, Kim S. High-resolution crystal structures of human cyclin-dependent kinase 2 with and without ATP: bound waters and natural ligand as guides for inhibitor design. J Med Chem 1996, 39:4540-4546. 10.1021/jm960402a, 8917641.
63. Brown N, Noble M, Endicott J, Johnson L. The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases. Nat Cell Biol 1999, 1:438-443. 10.1038/15674, 10559988.
64. Brown N, Noble M, Lawrie A, Morris M, Tunnah P, Divita G, Johnson L, Endicott J. Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity. J Biol Chem 1999, 274:8746-8756. 10.1074/jbc.274.13.8746, 10085115.
65. North B, Lehmann A, Dunbrack R. A new clustering of antibody CDR loop conformations. J Mol Biol 2011, 406:228-256. 10.1016/j.jmb.2010.10.030, 3065967, 21035459.
66. Deng Z, Chuaqui C, Singh J. Structural Interaction Fingerprint (SIFt): A novel method for analyzing three-dimensional protein - ligand binding interactions. J Med Chem 2003, 47:337-344.
67. Smith D, Radivojac P, Obradovic Z, Dunker K, Zhu G. Improved amino acid flexibility parameters. Protein Sci 2003, 12:1060-1072. 10.1110/ps.0236203, 2323876, 12717028.
68. Betzi S, Alam R, Martin M, Lubbers D, Han H, Jakkaraj S, Georg G, Schönbrunn E. Discovery of a potential allosteric ligand binding site in CDK2. ACS Chem Biol 2011, 6:492-501. 10.1021/cb100410m, 3098941, 21291269.
69. Janin J, Chothia C. The structure of protein-protein recognition sites. J Biol Chem 1990, 265:16027-16030.
70. Jarvis R, Broadhurst D, Johnson H, O'Boyle N, Goodacre R. PYCHEM: a multivariate analysis package for python. Bioinformatics 2006, 22:2565-2566. 10.1093/bioinformatics/btl416, 16882648.
71. Bourne Y, Watson M, Hickey M, Holmes W, Rocque W, Reed S, Tainer J. Crystal structure and mutational analysis of the human CDK2 kinase complex with cell cycle-regulatory protein CksHs1. Cell 1996, 84:863-874. 10.1016/S0092-8674(00)81065-X, 8601310.
72. Song H, Hanlon N, Brown N, Noble M, Johnson L, Barford D. Phosphoprotein-protein interactions revealed by the crystal structure of kinase-associated phosphatase in complex with phosphoCDK2. Mol Cell 2001, 7:615-626. 10.1016/S1097-2765(01)00208-8, 11463386.
73. Honda R, Lowe E, Dubinina E, Skamnaki V, Cook A, Brown N, Johnson L. The structure of cyclin E1/CDK2: implications for CDK2 activation and CDK2-independent roles. EMBO J 2005, 24:452-463. 10.1038/sj.emboj.7600554, 548659, 15660127.
74. Nolen B, Taylor S, Ghosh G. Regulation of protein kinases controlling activity through activation segment conformation. Mol Cell 2004, 15:661-675. 10.1016/j.molcel.2004.08.024, 15350212.
75. Young M, Gonfloni S, Superti-Furga G, Roux B, Kuriyan J. Dynamic coupling between the SH2 and SH3 domains of c-Src and Hck underlies their inactivation by C-terminal tyrosine phosphorylation. Cell 2001, 105:115-126. 10.1016/S0092-8674(01)00301-4, 11301007.
76. Kontopidis G, McInnes C, Pandalaneni S, McNae I, Gibson D, Mezna M, Thomas M, Wood G, Wang S, Walkinshaw M. Differential binding of inhibitors to active and inactive CDK2 provides insights for drug design. Chemistry Biol 2006, 13:201-211.
77. Perry J, Harris R, Moiani D, Olson A, Tainer J. p38alpha MAP kinase C-terminal domain binding pocket characterized by crystallographic and computational analyses. J Mol Biol 2009, 391:1-11. 10.1016/j.jmb.2009.06.005, 2724755, 19501598.
78. Comess K, Sun C, Abad-Zapatero C, Goedken E, Gum R, Borhani D, Argiriadi M, Groebe D, Jia Y, Clampit J, Haasch D, Smith H, Wang S, Song D, Coen M, Cloutier T, Tang H, Cheng X, Quinn C, Liu B, Xin Z, Liu G, Fry E, Stoll V, Ng T, Banach D, Marcotte D, Burns D, Calderwood D, Hajduk P. Discovery and characterization of Non-ATP site inhibitors of the mitogen activated protein (MAP) kinases. ACS Chem Biol 2010, 6:234-244.
79. Hardcastle IR, Arris CE, Bentley J, Boyle FT, Chen Y, Curtin NJ, Endicott JA, Gibson AE, Golding BT, Griffin RJ, Jewsbury P, Menyerol J, Mesguiche V, Newell DR, Noble MEM, Pratt DJ, Wang L-Z, Whitfield HJ. N2-substituted O6-cyclohexylmethylguanine derivatives: potent inhibitors of cyclin-dependent kinases 1 and 2. J Med Chem 2004, 47:3710-3722. 10.1021/jm0311442, 15239650.
80. Fischmann TO, Hruza A, Duca JS, Ramanathan L, Mayhood T, Windsor WT, Le HV, Guzi TJ, Dwyer MP, Paruch K, Doll RJ, Lees E, Parry D, Seghezzi W, Madison V. Structure-guided discovery of cyclin-dependent kinase inhibitors. Biopolymers 2008, 89:372-379. 10.1002/bip.20868, 17937404.
81. Schreyer AM, Blundell TL. CREDO: a structural interactomics database for drug discovery. Database (Oxford) 2013, 2013:bat049. 3715132, 23868908.
82. Davies TG, Tunnah P, Meijer L, Marko D, Eisenbrand G, Endicott JA, Noble MEM. Inhibitor binding to active and inactive CDK2: the crystal structure of CDK2-cyclin A/indirubin-5-sulphonate. Structure (London, England: 1993) 2001, 9:389-397.
83. Mizuguchi K, Deane CM, Blundell TL, Johnson MS, Overington JP. JOY: protein sequence-structure representation and analysis. Bioinformatics 1998, 14:617-623. 10.1093/bioinformatics/14.7.617, 9730927.
84. Hanks SK, Hunter T. Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J 1995, 9:576-596.
85. Mizuguchi K, Deane CM, Blundell TL, Overington JP. HOMSTRAD: A database of protein structure alignments for homologous families. Protein Sci 1998, 7:2469-2471. 10.1002/pro.5560071126, 2143859, 9828015.
86. Yazicioglu M, Goad D, Ranganathan A, Whitehurst A, Goldsmith E, Cobb M. Mutations in ERK2 Binding Sites Affect Nuclear Entry. J Biol Chem 2007, 282:28759-28767. 10.1074/jbc.M703460200, 17656361.
87. Hu S, Xie Z, Onishi A, Yu X, Jiang L, Lin J, Rho H, Woodard C, Wang H, Jeong J-S, Long S, He X, Wade H, Blackshaw S, Qian J, Zhu H. Profiling the human protein-DNA interactome reveals ERK2 as a transcriptional repressor of interferon signaling. Cell 2009, 139:610-622. 10.1016/j.cell.2009.08.037, 2774939, 19879846.
88. Meyer T, D'Abramo M, Hospital A, Rueda M, Ferrer-Costa C, Pérez A, Carrillo O, Camps J, Fenollosa C, Repchevsky D, Gelpí J, Orozco M. MoDEL (molecular dynamics extended library): A database of atomistic molecular dynamics trajectories. Structure 2010, 18:1399-1409. 10.1016/j.str.2010.07.013, 21070939.
89. Wang Z, Canagarajah BJ, Boehm JC, Kassisà S, Cobb MH, Young PR, Abdel-Meguid S, Adams JL, Goldsmith EJ. Structural basis of inhibitor selectivity in MAP kinases. Structure 1998, 6:1117-1128. 10.1016/S0969-2126(98)00113-0, 9753691.
90. Cock P, Antao T, Chang J, Chapman B, Cox C, Dalke A, Friedberg I, Hamelryck T, Kauff F, Wilczynski B, de Hoon M. Biopython: freely available Python tools for computational molecular biology and bioinformatics. Bioinformatics 2009, 25:1422-1423. 10.1093/bioinformatics/btp163, 2682512, 19304878.
91. NumPy, scientific computing with Python. [http://www.numpy.org/].
92. Python software for mathematics, science, and engineering. [http://www.scipy.org].
93. Pérez F, Granger BE. IPython: a system for interactive scientific computing. Comput Sci Eng 2007, 9:21-29.
94. The Python SQL toolkit and object relational mapper. [http://www.sqlalchemy.org/].
95. Sphinx Python documention generator. [http://sphinx-doc.org/].
96. Free source code hosting for Git and Mercurial. [https://bitbucket.org/].
97. Distributed source management tool. [http://mercurial.selenic.com/].
98. Harris JW, Stöcker H. Handbook of Mathematics and Computational Science 1998, Springer.
99. Do Carmo MP, Do Carmo MP. Differential geometry of curves and surfaces. Prentice-Hall Englewood Cliffs, NJ 1976, 2.
100. Hyberts S, Goldberg M, Havel T, Wagner G. The solution structure of eglin c based on measurements of many NOEs and coupling constants and its comparison with X-ray structures. Protein Sci 1992, 1:736-751. 10.1002/pro.5560010606, 2142248, 1304915.
101. Schmidtke P, Barril X. Understanding and predicting druggability. A high-throughput method for detection of drug binding sites. J Med Chem 2010, 53:5858-5867. 10.1021/jm100574m, 20684613.